Tags: 340B, hospital access, drug pricing, market access, HRSA, payer dynamics

Lilly's 340B cutoff is now an account-level access issue for hospital-facing field teams

By FieldPulse Editorial · June 22, 2026

Lilly's 340B dispute has moved from policy debate to real hospital-account friction after the company stopped discounts for providers that did not meet its paperwork requirements.

Eli Lilly has moved its 340B dispute from policy argument to account-level action.

According to Healthcare Dive, the company stopped paying 340B discounts to hospitals that did not comply with its new paperwork requirements late last week, and hospital groups are now urging the Health Resources and Services Administration to intervene.

That shift matters because 340B is not an abstract Washington topic for many field teams.

It changes the tone of conversations with hospital systems, outpatient departments, and access stakeholders who are already sensitive to purchasing terms, reimbursement pressure, and manufacturer restrictions.

When a major manufacturer actually cuts off discounts, the issue becomes operational for accounts that believe they are entitled to the savings.

Healthcare Dive reported earlier this month that Lilly had warned hospitals they needed to share claims data tied to in-house pharmacy dispensing.

Lilly's position is that the added documentation is needed to prevent duplicate discounts across federal programs.

Hospital groups have pushed back hard, arguing the policy creates new administrative burden and threatens the economics of 340B purchasing.

That distinction matters in the field because accounts will not experience this as a policy memo.

They will experience it as a purchasing and access problem.

Hospital customers are likely to focus less on the legal rationale and more on whether their expected discount flow changes, whether internal pharmacy teams need to submit new documentation, and whether similar restrictions could touch other products or sites of care.

For Lilly field teams, the practical takeaway is not to improvise policy explanations.

Accounts may ask whether specific drugs still qualify for 340B pricing, what documentation is now required, and whether the restriction could spread.

Reps should expect those questions, stay tightly aligned to company-approved access messaging, and understand that the account concern is likely to cen.